Renal Cell Carcinoma

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.

Positive results have been reported from phase 1/2 KEYMAKER-U03B study, and belzutifan plus lenvatinib is being further investigated in the phase 3 LITESPARK-011 study (NCT04586231).

Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.

While cabozantinib, nivolumab, and ipilimumab resulted in a longer progression-free survival among patients with renal cell carcinoma vs nivolumab and ipilimumab alone, more adverse events were observed with the combination.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hans Hammers, MD, PhD, and participants discussed their experiences using lenvatinib to treat patients with advanced clear cell renal cell carcinoma.

Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.

A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.

In an interview with Targeted Oncology, Samer A. Srour, MD, discussed the results from the phase 3 TRAVERSE study and the potential role of chimeric antigen receptor T-cell therapy in renal cell carcinoma.

Hans Hammers, MD, PhD, discusses the evolving treatment paradigms in patients with advanced renal cell carcinoma and how recent clinical trial data may optimize future treatment selections.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, reviewed updated results of trial of frontline combination therapies for patients with advanced renal cell carcinoma.

RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.

Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.

In the third article of this series, Bradley McGregor, MD, gives comprehensive insights on treating patients with advanced renal cell carcinoma, with a focus on treatment sequencing.

Phase 2 study results further demonstrate the promise of using belzutifan in combination with cabozantinib for the treatment of patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.

Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.

A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.

The prespecified interim analysis of the RENOTORCH study showed toripalimab plus axitinib improved progression-free survival, overall response rates, and showed no new safety signals among patients with renal cell carcinoma.

Bradley McGregor, MD, discusses the current landscape for advanced renal cell carcinoma therapies, emerging clinical evidence, and considerations for optimal treatment sequencing.